Text Size: AAA

Press Releases

Learn about Santen USA's announcements, achievements, and updates—all of which are downloadable as PDFs below. For global press releases, visit Santen Worldwide.

rss feed

2017

  • May 2017
    Osaka, Japan

    Santen Pharmaceutical Co., Ltd. today announced consolidated performance for FY16, the year ended March 31, 2017.

    Download PDF

  • May 2017
    Osaka, Japan

    Santen to Establish a Corporate Venture Capital Fund in the United States

    Download PDF

  • Apr. 2017
    Osaka, Japan

    Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Intravitreal Sirolimus (DE-109) in the Treatment of Non-Infectious Uveitis of the Posterior Segment

    Download PDF

  • Apr. 2017
    Osaka, Japan and Portola Valley, CA, USA

    Santen Announces Strategic Investment in Regenerative Patch Technologies LLC ("RPT").

    Download PDF

  • Mar. 2017
    Osaka, Japan

    Santen and Singapore Eye Research Institute (Seri) Announce an Expanded Relationship Including the Creation of a New Joint Laboratory to Develop Novel Ophthalmic Therapeutics, Diagnostics and Devices

    Download PDF

  • Feb. 2017
    Osaka, Japan

    Santen and twoXAR Announce Strategic Research Collaboration to Discover New Glaucoma Treatments

    Download PDF

  • Feb. 2017
    Osaka, Japan

    Santen Reports Consolidated Performance For the Third Quarter of FY2016

    Download PDF

2016

  • Nov. 2016
    Osaka, Japan

    Santen Announces Phase III SAKURA Program Topline Results in Patients with Non-Infectious Uveitis of the Posterior Segment

    Download PDF

  • Oct. 2016
    Osaka, Saitama and Hyogo, Japan

    Santen, RIKEN and FBRI Announce Research Collaboration to Develop New Retinal Disease Treatments

    Download PDF

  • Aug. 2016
    Osaka, Japan and London, UK

    Santen and University College London Announce Research Collaboration

    Download PDF

  • Jul. 2016
    Osaka, Japan and Miami, FL, U.S.

    Santen to Acquire InnFocus, Developer of "MicroShunt" Glaucoma Implant Device

    Download PDF

2015

  • Mar. 2015
    Osaka, Japan

    Santen Pharmaceutical Co., Ltd. today announced it received approval of the Marketing Authorization Application (MAA) for Ikervis from the European Commission (EC)

    Download PDF

  • Mar. 2015
    Osaka, Japan

    European medicines agency accepts Santen’s marketing application filing for intravitreal sirolimus for the treatment of noninfectious uveitis of the posterior segment

    Download PDF

  • Jan. 2015
    Osaka, Japan

    Santen receives a Positive CHMP Opinion for EU Marketing Authorization for Ikervis®

    Download PDF

2014

  • Nov. 2014
    Osaka, Japan
    Singapore

    Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Diabetic Macular Edema (DME), its Fourth Indication

    Download PDF

  • Nov. 2014
    Osaka, Japan
    Singapore

    Santen and Singapore Eye Research Institute(SERI) announce a collaboration to develop new ophthalmic therapeutics

    Download PDF

  • July 2014
    Osaka, Japan

    Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck

    Download PDF

  • May 2014
    Osaka, Japan

    Santen Announces the Signing of Agreement between Merck for the Purchase of Assets in Ophthalmology

    Download PDF

  • Apr. 2014
    Emeryville, CA

    Ram Palanki Appointed VP- Strategic Marketing & Sales at Santen

    Download PDF

  • Apr. 2014
    Osaka, Japan

    Santen Partners with Akorn, Inc. subsidiary Oak Pharmaceuticals for Marketing of Tafluprost, the Treatment of Glaucoma and Ocular Hypertension in the U.S.

    Download PDF

  • Apr. 2014
    Emeryville, CA

    Santen Phase III study meets primary endpoint for the treatment of non-infectious posterior segment uveitis (NI-PSU)

    Download PDF

  • Mar. 2014
    San Diego, CA,
    Osaka, Japan

    Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology

    Download PDF

2013

  • Mar. 2013
    Emeryville, CA

    Santen Ltd. announces change in management structure for U.S. subsidiary organization

    Download PDF

  • Jan. 2013
    Emeryville, CA

    Santen Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. enter into financing and research collaboration agreements for posterior ocular disease

    Download PDF

2012

  • Mar. 2012
    Emeryville, CA

    Santen Inc. appoints Senior Director, Healthcare Economics, Reimbursement, and Market Access.

    Download PDF

2011

  • Nov. 2011
    Emeryville, CA

    Santen announces FDA orphan drug status for sirolimus (DE-109).

    Download PDF

  • Sept. 2011
    Emeryville, CA

    Santen announces EMA orphan drug status for sirolimus (DE-109).

    Download PDF

  • July 2011
    Emeryville, CA

    Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. of Osaka, Japan, announced the addition of four new employees to the Global Clinical and Medical Affairs Group.

    Download PDF

  • June 2011
    Napa, CA

    Santen announces the initiation of a multinational Phase III program evaluating sirolimus (DE-109) for the treatment of non-infectious posterior uveitis.

    Download PDF

  • Apr. 2011
    Napa, CA

    Santen Inc. announces relocation of US corporate headquarters.

    Download PDF

2010

  • Nov. 2010
    Napa, CA

    Santen Inc. appoints Associate Director of Strategic Marketing.

    Download PDF

  • May 2010
    Napa, CA

    Santen Inc. appoints Vice President of Clinical Affairs.

    Download PDF

  • May 2010
    Osaka, Japan

    Clinical Data, Inc. licenses adenosine A2A agonist to Santen for development of ophthalmic treatments.

    Download PDF

  • Apr. 2010
    Osaka, Japan

    Santen and Inspire announce approval of DIQUASTM for dry eye treatment in Japan.

    Download PDF

  • Mar. 2010
    Osaka, Japan

    Santen Ltd. announces change in management structure for U.S. subsidiary organization.

    Download PDF

  • Feb. 2010
    Napa, CA

    Ophthalmic Women Leaders (OWL) names Pamela Gleeson, CFO of Santen Inc., as 2010 President.

    Download PDF

2009

  • Nov. 2009
    Napa, CA

    Santen CEO Adrienne Graves joins Board of ASCRS Foundation.

    Download PDF

  • Oct. 2009
    Napa, CA

    Santen CEO Adrienne Graves joins Board of Glaucoma Research Foundation.

    Download PDF

  • Mar. 2009
    Napa, CA

    Santen announces Director of Business Development.

    Download PDF

  • Aug. 2009
    Napa, CA

    Santen expands business development operations.

    Download PDF

2008

  • Oct. 2008
    Napa, CA

    Santen announces new Vice President of Research & Development.

    Download PDF

2007

  • Oct. 2007
    Napa, CA

    Santen announces Vistakon Pharmaceuticals to launch IQUIX® in the U.S.

    Download PDF

  • May 2007
    Napa, CA

    Susan Schneider, M.D. joins Santen, Inc. as Vice President of Clinical Affairs.

    Download PDF

  • Feb. 2007
    Osaka, Japan

    Santen announces proposed dividends change.

    Download PDF

  • Feb. 2007
    Osaka, Japan

    Changes in significant shareholder.

    Read more

  • Jan. 2007
    Osaka, Japan

    Santen announces financial result for the third quarter ended December 31, 2006.

    Read more

2006

  • July 2006
    Osaka, Japan

    Announcement for the financial result for the first quarter ended June 30, 2006 full report:

    Download PDF

  •  

    Appendix: FY2006 first quarter (three months ended June 30, 2006).

    Download PDF

  • July 2006
    Osaka, Japan

    2006-2010 Medium-term management plan.

    Download PDF

  • Mar. 2006
    Osaka, Japan

    Agreement concerning microsphere-based platform development and license.

    Download PDF

  • Mar. 2006
    Tokyo, Japan

    Agreement concerning joint research of ophthalmic drug.

    Download PDF

  • Feb. 2006
    Napa, CA

    Santen announces new Vice President of Strategic Marketing & Business Development: Schalon Newton brings international experience to Santen’s U.S. team.

    Download PDF

  • Jan. 2006
    Osaka, Japan

    Santen launches PAPILOCK Mini ophthalmic solution 0.1%.

    Download PDF

2005

  • Oct. 2005
    Osaka, Japan

    Santen receives manufacturing and marketing approval for its Vernal Keratoconjunctivitis treatment, PAPILOCK Mini ophthalmic solution 0.1%.

    Download PDF

  • Sep. 2005
    Osaka, Japan

    Santen establishes subsidiary in China.

    Download PDF

  • Sep. 2005
    Osaka, Japan

    Agreement concerning CS-011 as dry eye drug candidate.

  • May 2005
    Napa, CA

    OccuLogix appoints Santen CEO Adrienne L. Graves, Ph.D. to Board of Directors.

    Download PDF

2004

  • Oct. 2004

    Agreement concerning development of novel anti-rheumatic agent anti-APO-1 antibody in Japan.

    Download PDF

  • July 2004

    The Eyes Have It: ophthalmic pharmaceutical company Santen Inc. sees a bright future in Napa.

    Download PDF

  • Apr. 2004
    Napa, CA

    Doctor addresses Santen on Guatemala outreach.

    Download PDF

  • Mar. 2004
    Osaka, Japan

    Santen receives FDA approval of Iquix®, new treatment for sight-threatening condition Levofloxacin 1.5% is third Santen-developed product approved in recent years.

    Download PDF

2003

  • Dec. 2003
    Napa, CA

    Santen signs agreement with Johnson & Johnson Vision Care, Inc. to supply prescription ophthalmic products.

    Download PDF

  • July 2003
    San Francisco, CA

    “Prevent Blindness Day” at San Francisco’s Pac Bell Park.

    Download PDF

Thank you for visiting Santen USA

Click continue to be redirected to Santen Worldwide at www.santen.com